He Social Health Insurance (EsSalud) reported this Saturday that the supply crisis Tacrolimus It is, for the moment, controlled, after complaints made by patients and relatives who warned about the lack of the medication in various establishments. According to the entity, this advance reduces the risk of severe complications in transplant recipients, for whom suspension of treatment can mean rejection of the organ or even death.
The institution recalled that Tacrolimus is a drug for permanent use for those who have received a transplant, so its continuous supply is essential. The announcement of the regularization of the stock seeks to restore peace of mind to hundreds of patients who, in recent weeks, were forced to look for the medicine on their own or reduce their doses due to the shortage.
Distribution of 129 thousand tablets to hospitals and networks
According to official information, a total of 129,420 Tacrolimus tablets will be distributed progressively starting this Saturday, December 13 and Sunday, December 14. The lots will be destined for the Guillermo Almenara Irigoyen, Edgardo Rebagliati Martins and Alberto Sabogal Sologuren national hospitals, as well as the care networks of Arequipa and La Libertad.
Along these lines, EsSalud specified that the distribution will be carried out in a staggered manner, depending on the needs of each establishment and the number of transplant patients treated. Although it is an immediate response to the crisis, EsSalud clarified that this delivery does not yet constitute the structural solution to the drug supply problem.
Temporary measures and plan for annual supply
The entity explained that it is in the process of acquiring a larger batch of Tacrolimus, with the aim of guaranteeing a full year’s supply to all patients who require this treatment. Meanwhile, Social Security continues to apply temporary measures to avoid new stock shortages and ensure the continuity of therapies.
Along these lines, the institution stressed that the current distribution of tablets makes it possible to cover immediate demand and prevent patients from being exposed again to the uncertainty generated by shortages. However, he reiterated that the true solution will come with the formalization and delivery of the annual batch in the process of acquisition.
Support from the Minsa and delivery of a third batch
The Ministry of Health reported that, as part of the temporary support provided to EsSalud, a third batch of Tacrolimus was delivered to the Social Security central warehouse. This provision was made based on existing availability and under the commitment not to affect the treatment of patients treated in Minsa or regional government hospitals.
The Health Ministry highlighted that this support is part of inter-institutional coordination aimed at guaranteeing that no transplant patient is left without access to the medicine. Support will continue while EsSalud completes its own purchasing processes and ensures stable supply in the medium term.
